Summary
Novo Nordisk's chief executive, Mike Doustdar, believes investors are underestimating the potential of the company's drugs, despite being a year into a corporate turnaround.
Novo Nordisk CEO: Investors Underestimate Drug Promise Amid Turnaround
HyperFast News
Related news
Novo Nordisk Struggles to Find Next Blockbuster Drug After Wegovy's Success, Faces Trial Failure and Competition
14 Sept 2026, 5:49 pm · News
Novo Nordisk Market Value Drops $30 Billion After Failed Heart Drug Trial
14 Sept 2026, 5:49 pm · News
Novo Nordisk Files for Injunction to Block Eli Lilly Weight-Loss Drug Ads
14 Sept 2026, 5:49 pm · News
